Non-Hodgkin Lymphoma

The United Kingdom’s National Institute for Health and Care Excellence has chosen not to recommend polatuzumab vedotin plus rituximab and bendamustine for use in adult patients with relapsed/refractory diffuse large B-cell lymphoma who cannot undergo hematopoietic stem cell transplant.

Stephen J. Schuster, MD, discusses promising findings and next steps for mosunetuzumab in patients with relapsed/refractory non-Hodgkin lymphoma.

Benjamin Heyman, MD, discusses frontline and maintenance therapy options, novel targeted approaches, and the expanding role of minimal residual disease in patients with follicular lymphoma.

Dimitrios Tzachanis, MD, PhD, discusses updates and remaining questions with CAR T-cell therapy.

Erin Reid, MD, discusses the treatment advances across lymphomas and the remaining questions that need to be answered with further research.